Skip to content
IGI grad logo
  • About Us
    • Our Approach NewGreenArrow
      Centers of Innovation NewGreenArrow
      Management Team NewGreenArrow
      Board of Directors NewGreenArrow
      Scientific Advisory Board NewGreenArrow
      Our Approach NewGreenArrow
      Centers of Innovation NewGreenArrow
      Our Team NewGreenArrow
      Leadership
      Governance Board
      Scientific Advisory Board
  • Corporate Presentation
  • Pipeline
  • Partnerships
  • News Center
    • News & Media NewGreenArrow
      Publications NewGreenArrow
  • Careers
    • Our Culture NewGreenArrow
      Join Us NewGreenArrow
  • Home
  • About Us
    • Our Approach
    • Centers of Innovation
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Corporate Presentation
  • Pipeline
  • Partnerships
    • Partnerships
  • News Center
    • News & Media
    • Publications
  • Careers
    • Our Culture
    • Join Us
  • Contact Us
  • Home
  • About Us
    • Our Approach
    • Centers of Innovation
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Corporate Presentation
  • Pipeline
  • Partnerships
    • Partnerships
  • News Center
    • News & Media
    • Publications
  • Careers
    • Our Culture
    • Join Us
  • Contact Us

corporate

  1. Home>
  2. corporate

Corporate update – August 2024 Update

  • Post published:August 13, 2024
  • Post category:corporate

DATE: 13 August 2024 CATEGORY: CORPORATE UPDATE August 2024 Update About IGIIchnos Glenmark Innovation (IGI) is an alliance between Ichnos Sciences Inc., a global fully integrated clinical-stage biotech company developing multispecifics™…

Continue ReadingCorporate update – August 2024 Update

Recent Updates

  • Ichnos Glenmark Innovation (IGI) Announces Global Commercialization Strategy for ISB 2001 Following Licensing Deal with AbbVie
    July 10, 2025/
    0 Comments
  • Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody
    July 9, 2025/
    0 Comments
  • Full Dose-Escalation Data Show Continued High Response Rates and Favorable Safety Profile of ISB 2001, a First-in-Class BCMA × CD38 × CD3 Trispecific Antibody, for the Treatment of Relapsed/Refractory Multiple Myeloma
    June 2, 2025/
    0 Comments
  • Ichnos Glenmark Innovation (IGI) Receives U.S. FDA Fast Track Designation for ISB 2001 for Relapsed/Refractory Multiple Myeloma
    May 3, 2025/
    0 Comments
  • Ichnos Glenmark Innovation (IGI) Presents First Clinical Data from Phase 1 Study of Trispecific TREAT™ Antibody, ISB 2001, Showing High Overall Response Rate (ORR) with Durable Responses and Favorable Safety Profile in Patients with Heavily Pretreated Multiple Myeloma​
    December 9, 2024/
    0 Comments

We are open for collaboration

Contact Us
For the latest updates, follow us on
  • Linkedin

Want to create something cutting edge with us? Join us.

We are open for collaboration

For the latest updates, follow us on
  • Linkedin

Want to create something cutting edge with us? Join us.

Contact Us
Ichnos Glenmark Innovation creates cutting-edge solutions to treat haematological malignancies and solid tumours to bring new hope for patients and healthcare professionals alike.
  • Terms of Use
  • Privacy Policy
  • Cookies Policy

Get in Touch

© Copyright 2025. All Rights Reserved by IGI.

© Copyright 2025. All Rights Reserved by IGI.

  • Terms of Use
  • Privacy Policy
  • Cookies Policy
  • Expanded Access Policy
  • Contact Us
  • Linkedin